Tokyo Tape
Sign in
← Trans Genic

Quarterly report · Q2

2342.TEDINET S100PJSQ
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 48
MetricValuePeriodScopeSource row
Revenue¥5.5bn2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥12.6bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥6.7bn2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥135m2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥1.6bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥204m2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥1.8bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥1.5bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥157m2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥1.5bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥55m2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥1.9bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥982m2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥55m2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥976m2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥10.7bnat 2022-09-30Cons.Assets
Total assets¥10.4bnat 2022-03-31Cons.Assets
Total assets¥10.4bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥4.0bnat 2022-09-30Cons.Liabilities
Total liabilities¥3.8bnat 2022-03-31Cons.Liabilities
Net assets / equity¥6.6bnat 2022-09-30Cons.Net assets
Net assets / equity¥6.6bnat 2022-03-31Cons.Net assets
Net assets / equity¥5.9bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥3.5bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥4.6bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥3.4bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥4.6bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥3.4bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥3.0bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow−¥696m2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥1.8bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥883m2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥601m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow¥982m2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥238m2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥65m2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥1.2bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥320m2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥3.262022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥4.792022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥109.522021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥56.562021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥21.522021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥109.312021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥56.42021-04-01 → 2021-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio60.8%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio62.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio55.4%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 31
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥2m
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-09-30¥1m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥3m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥111m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥1.3bn
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.3bn
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥153m
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥4.3bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥4.3bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥187,000
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥92m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥5.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥5.5bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥3m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥246m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥6m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥6m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥97m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥3.1bn
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥3.1bn
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥6m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.6bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥3.6bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥3.6bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥261,000
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥117m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-09-30¥6.7bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-09-30¥6.7bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-09-30¥6m
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-09-30¥1.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 513
ItemContextValueUnit
Selling general and administrative expensesPrior1YTDDuration961692000JPY
Selling general and administrative expensesCurrentYTDDuration976732000JPY
Operating incomePrior1YTDDuration1602297000JPY
Operating incomeCurrentYTDDuration134775000JPY
Interest income noiPrior1YTDDuration437000JPY
Interest income noiCurrentYTDDuration378000JPY
Foreign exchange gains noiPrior1YTDDuration－JPY
Foreign exchange gains noiCurrentYTDDuration5816000JPY
Insurance income noiPrior1YTDDuration6007000JPY
Insurance income noiCurrentYTDDuration2604000JPY
Subsidy income noiPrior1YTDDuration2738000JPY
Subsidy income noiCurrentYTDDuration－JPY
Insurance premiums refunded cancellation noiPrior1YTDDuration－JPY
Insurance premiums refunded cancellation noiCurrentYTDDuration155376000JPY
Other noiPrior1YTDDuration3846000JPY
Other noiCurrentYTDDuration7900000JPY
Non operating incomePrior1YTDDuration13030000JPY
Non operating incomeCurrentYTDDuration172076000JPY
Interest expenses noePrior1YTDDuration11070000JPY
Interest expenses noeCurrentYTDDuration13073000JPY
Foreign exchange losses noePrior1YTDDuration7385000JPY
Foreign exchange losses noeCurrentYTDDuration－JPY
Acquisition expenses noePrior1YTDDuration36092000JPY
Acquisition expenses noeCurrentYTDDuration80000000JPY
Other noePrior1YTDDuration19792000JPY
Other noeCurrentYTDDuration9469000JPY
Non operating expensesPrior1YTDDuration74340000JPY
Non operating expensesCurrentYTDDuration102543000JPY
Ordinary incomePrior1YTDDuration1540987000JPY
Ordinary incomeCurrentYTDDuration204309000JPY
Subsidy eiPrior1YTDDuration239451000JPY
Subsidy eiCurrentYTDDuration－JPY
Extraordinary incomePrior1YTDDuration239451000JPY
Extraordinary incomeCurrentYTDDuration－JPY
Impairment loss elPrior1YTDDuration－JPY
Impairment loss elCurrentYTDDuration47756000JPY
Loss on reduction of noncurrent assets elPrior1YTDDuration239451000JPY
Loss on reduction of noncurrent assets elCurrentYTDDuration－JPY
Extraordinary lossPrior1YTDDuration239451000JPY
Extraordinary lossCurrentYTDDuration47756000JPY
Income before income taxesPrior1YTDDuration1540987000JPY
Income before income taxesCurrentYTDDuration156552000JPY
Income taxes currentPrior1YTDDuration587555000JPY
Income taxes currentCurrentYTDDuration8164000JPY
Income taxes deferredPrior1YTDDuration-22879000JPY
Income taxes deferredCurrentYTDDuration93864000JPY
Income taxesPrior1YTDDuration564676000JPY
Income taxesCurrentYTDDuration102028000JPY
Profit lossPrior1YTDDuration976310000JPY
Profit lossCurrentYTDDuration54523000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass